Pfizer joins the omicron data party, linking adapted vaccine to increased immune response ahead of FDA meeting

The variant-adapted COVID-19 vaccine updates are now coming thick and fast. Days after Moderna and Sanofi shared data, Pfizer and BioNTech have stepped into the limelight with immune response results for their monovalent and bivalent omicron-adapted mRNA vaccines.